Results 41 to 50 of about 71,002 (280)

Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]

, 2014
The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John, Boyd, Marie, Hutchison, Sharon, Mairs, Robert, Rae, Colin, Tesson, Mathias   +5 more
core   +1 more source

Pan-cancer landscape of homologous recombination deficiency

Nature Communications, 2020
Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen, John W. M. Martens, Arne Van Hoeck, Edwin Cuppen   +3 more
doaj   +1 more source

Background-Quenched Aggregation-Induced Emission through Electrostatic Interactions for the Detection of Poly(ADP-ribose) Polymerase-1 Activity

Molecules, 2023
Poly(ADP-ribose) polymerase-1 (PARP1) is a potential biomarker and therapeutic target for cancers that can catalyze the poly-ADP-ribosylation of nicotinamide adenine dinucleotide (NAD+) onto the acceptor proteins to form long poly(ADP-ribose) (PAR ...
Fengli Gao, Ruimin Zhao, Liping Huang, Xinyao Yi   +3 more
doaj   +1 more source

PARP-1 regulates DNA repair factor availability. [PDF]

, 2018
PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic
Birbe, Ruth, Brand, Lucas J, Cendon-Florez, Ylenia, Chand, Saswati N., de Leeuw, Renée, Dicker, Adam, MD, PhD, Dylgjeri, Emanuela, Evans, Joseph, Feng, Felix Y, Gallagher, Peter, Gaur, Sanchaika, Gomella, Leonard G, Gordon, Nicolas, Han, Sumin, Huang, Fangjin, Kelly, William Kevin, Knudsen, Beatrice, Knudsen, Karen E, Lallas, Costas D, Leiby, Benjamin E, Mandigo, Amy C., McCann, Jennifer J, McCue, Peter, McNair, Christopher, Parsons, Theodore, Poudel Neupane, Neermala, Raj, Ganesh V, Schiewer, M J, Shafi, Ayesha A, Trabulsi, Edouard J, Visakorpi, Tapio, Zhao, Shuang G   +31 more
core   +2 more sources

Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics [PDF]

Acta Pharmacologica Sinica, 2010
The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects.
Jin-xue, He, Chun-hao, Yang, Ze-hong, Miao   +2 more
openaire   +2 more sources

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Biomedicine & Pharmacotherapy, 2023
Poly-ADP-ribose polymerase (PARP) plays an important role in DNA damage detection and repair. PARP inhibitors (PARPi) are a novel class of targeted agents used widely in the treatment of female cancer patients with BRCA mutations, including younger patients.
Jiajia, Li, Qingchao, Li, Lingyi, Zhang, Songling, Zhang, Yun, Dai   +4 more
openaire   +2 more sources

PARP-3 and APLF function together to accelerate nonhomologous end joining [PDF]

, 2010
PARP-3 is a member of the ADP-ribosyl transferase superfamily of unknown function. We show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to accelerate
Ahel, Ame, Anna E.O. Fisher, Audebert, Bekker-Jensen, Benjamin, Bernardo Reina-San-Martin, Boulton, Brown, Bryant, Bryant, Caldecott, Caldecott, Critchlow, Ding, Drouet, El-Khamisy, Farmer, Fisher, Grawunder, Guy Poirier, Hochegger, Hottiger, Iles, Isabelle Robert, Kanno, Keith W. Caldecott, Kickhoefer, Kleine, Le Page, Lehtio, Limei Ju, Lobrich, Loseva, Macrae, Mahaney, Maria C. Zuma, Mehrotra, Michele Rouleau, Morrison, Okano, Otto, Poirier, Robert, Roberts, Rogakou, Rogakou, Rouleau, Rulten, Smith, Soulas-Sprauel, Stevnsner, Stuart L. Rulten, Sugimura, Trucco, Wang, Yan, Yang, Yano, Yano   +59 more
core   +1 more source

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]

, 2012
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, John W, Boyd, Marie, Champion, Sue, Gaze, Mark N, Mairs, Robert J, McCluskey, Anthony G, Pimlott, Sally L, Tesson, Mathias   +7 more
core   +1 more source